MX2015003501A - Metodos para tratar hepatitis c - Google Patents

Metodos para tratar hepatitis c

Info

Publication number
MX2015003501A
MX2015003501A MX2015003501A MX2015003501A MX2015003501A MX 2015003501 A MX2015003501 A MX 2015003501A MX 2015003501 A MX2015003501 A MX 2015003501A MX 2015003501 A MX2015003501 A MX 2015003501A MX 2015003501 A MX2015003501 A MX 2015003501A
Authority
MX
Mexico
Prior art keywords
methods
treating hepatitis
inhibitors
hepatitis
hcv
Prior art date
Application number
MX2015003501A
Other languages
English (en)
Other versions
MX367796B (es
Inventor
Warren M Kati
Mark A Matulenko
Ryan G Keddy
John K Pratt
Clarence J Maring
Rolf Wagner
Dachun Liu
Preethi Krishnan
Teresa Lok-Chan Ng
Tami J Pilot-Matias
Neeta C Mistry
Thomas J Reisch
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49304326&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2015003501(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX2015003501A publication Critical patent/MX2015003501A/es
Publication of MX367796B publication Critical patent/MX367796B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se describen inhibidores de VHC pan-genotípicos. Esta invención también se relaciona a métodos para utilizar estos inhibidores para utilizar estos inhibidores para tratar infección por VHC.
MX2015003501A 2012-09-18 2013-09-17 Usos médicos para tratar hepatitis c. MX367796B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261702564P 2012-09-18 2012-09-18
PCT/US2013/060103 WO2014047039A1 (en) 2012-09-18 2013-09-17 Methods for treating hepatitis c

Publications (2)

Publication Number Publication Date
MX2015003501A true MX2015003501A (es) 2015-10-26
MX367796B MX367796B (es) 2019-09-06

Family

ID=49304326

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015003501A MX367796B (es) 2012-09-18 2013-09-17 Usos médicos para tratar hepatitis c.
MX2019010600A MX2019010600A (es) 2012-09-18 2015-03-18 Usos médicos para tratar hepatitis c.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019010600A MX2019010600A (es) 2012-09-18 2015-03-18 Usos médicos para tratar hepatitis c.

Country Status (25)

Country Link
US (1) US20140080868A1 (es)
EP (2) EP2897611B1 (es)
JP (4) JP6297044B2 (es)
CN (1) CN104797253A (es)
AU (2) AU2013318302B2 (es)
BR (1) BR112015006037B1 (es)
CA (1) CA2884539C (es)
CY (1) CY1122442T1 (es)
DK (1) DK2897611T3 (es)
ES (1) ES2755089T3 (es)
HK (1) HK1209319A1 (es)
HR (1) HRP20191939T1 (es)
HU (1) HUE046544T2 (es)
LT (1) LT2897611T (es)
MX (2) MX367796B (es)
NZ (1) NZ630581A (es)
PL (1) PL2897611T3 (es)
PT (1) PT2897611T (es)
RS (1) RS59640B1 (es)
RU (1) RU2665365C2 (es)
SG (2) SG11201502095SA (es)
SI (1) SI2897611T1 (es)
TW (1) TWI621436B (es)
WO (1) WO2014047039A1 (es)
ZA (1) ZA201501752B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104797253A (zh) * 2012-09-18 2015-07-22 艾伯维公司 用于治疗丙型肝炎的方法
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
SI3213750T1 (sl) * 2013-03-14 2020-11-30 Abbvie Inc. Kombinacija dveh antivirusnih sredstev za zdravljenje hepatitisa C
MX2016012722A (es) * 2014-04-02 2016-12-16 Abbvie Inc Metodos para tratar el virus de la hepatitis c.
JP6632992B2 (ja) 2014-04-02 2020-01-22 アッヴィ・インコーポレイテッド Ｈｃｖを処置するための方法
EP3313378A1 (en) * 2015-06-26 2018-05-02 AbbVie Inc. Solid pharmaceutical compositions for treating hcv
US20160375017A1 (en) 2015-06-26 2016-12-29 Abbvie Inc. Solid Pharmaceutical Compositions for Treating HCV
EP3319604A1 (en) * 2015-07-08 2018-05-16 AbbVie Inc. Methods for treating hcv
JP7133466B2 (ja) * 2015-07-17 2022-09-08 アッヴィ・インコーポレイテッド Ｈｃｖを処置するための固体医薬組成物
CN109689063A (zh) 2016-04-28 2019-04-26 埃默里大学 含有炔烃的核苷酸和核苷治疗组合物及其相关用途
GB202113944D0 (en) * 2021-09-29 2021-11-10 Univ Liverpool Injectable formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR059429A1 (es) * 2006-02-09 2008-04-09 Schering Corp Combinaciones que involucran el (los) inhibidor(es) de la protesa hcv y metodos de tratamiento relacionados al (los) mismo (s)
AR075584A1 (es) * 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
US8937150B2 (en) * 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US9394279B2 (en) * 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
MX2014004729A (es) * 2011-10-21 2014-07-28 Abbvie Inc Tratamiento en combinacion (por ejemplo, con abt-072 o abt-333) de agentes antivirales de accion directa para utilizarse en el tratamiento del virus de la hepatitis c.
CN104797253A (zh) * 2012-09-18 2015-07-22 艾伯维公司 用于治疗丙型肝炎的方法

Also Published As

Publication number Publication date
ES2755089T3 (es) 2020-04-21
EP2897611B1 (en) 2019-07-24
AU2013318302A1 (en) 2015-04-02
ZA201501752B (en) 2016-08-31
HK1209319A1 (en) 2016-04-01
MX2019010600A (es) 2020-02-03
PT2897611T (pt) 2019-11-27
RS59640B1 (sr) 2020-01-31
WO2014047039A1 (en) 2014-03-27
PL2897611T3 (pl) 2020-03-31
TWI621436B (zh) 2018-04-21
TW201412311A (zh) 2014-04-01
CY1122442T1 (el) 2021-01-27
HUE046544T2 (hu) 2020-03-30
JP2015528511A (ja) 2015-09-28
HRP20191939T1 (hr) 2020-01-10
MX367796B (es) 2019-09-06
RU2015114543A (ru) 2016-11-10
AU2013318302B2 (en) 2018-02-22
EP3597190A1 (en) 2020-01-22
JP6297044B2 (ja) 2018-03-20
CA2884539C (en) 2022-06-21
EP2897611A1 (en) 2015-07-29
JP2018109035A (ja) 2018-07-12
LT2897611T (lt) 2019-12-10
US20140080868A1 (en) 2014-03-20
CN104797253A (zh) 2015-07-22
AU2018203608A1 (en) 2018-06-14
BR112015006037A2 (pt) 2017-07-04
RU2665365C2 (ru) 2018-08-29
BR112015006037B1 (pt) 2022-05-17
DK2897611T3 (da) 2019-11-04
SI2897611T1 (sl) 2019-12-31
AU2018203608B2 (en) 2019-12-19
JP2019194241A (ja) 2019-11-07
JP2021054849A (ja) 2021-04-08
SG11201502095SA (en) 2015-05-28
CA2884539A1 (en) 2014-03-27
SG10201702248UA (en) 2017-04-27
JP6556884B2 (ja) 2019-08-07
NZ630581A (en) 2017-02-24

Similar Documents

Publication Publication Date Title
MX2019010600A (es) Usos médicos para tratar hepatitis c.
PH12017550022A1 (en) Phosphoramidates for the treatment of hepatitis b virus
MX336580B (es) Metodos para el tratamiento de vhc.
SA516370684B1 (ar) مثبطات بوليمراز فيروس الالتهاب الكبدي سي
EA201391152A1 (ru) Ингибиторы вируса гепатита с
EA201691261A1 (ru) Новые дигидрохинолизиноны для лечения и профилактики инфекции, вызванной вирусом гепатита b
EA201390190A1 (ru) Ингибиторы вируса гепатита с
EA030115B9 (ru) Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
MX2016005393A (es) Metodos para tratar vhc.
GB201103062D0 (en) Method
EA201270616A1 (ru) Ингибиторы вируса гепатита с
PH12015501017A1 (en) Alternative uses for hbv assembly effectors
GEP201706757B (en) Substituted nucleosides, nucleotides and analogs thereof
PH12014502513A1 (en) Nampt inhibitors
MX2014013752A (es) Inhibidores de nampt.
SG195383A1 (en) Yeast-based compositions and methods for the treatment or prevention of hepatitis delta virus infection
EA201591705A1 (ru) Композиции и способы для диагностики и лечения рака печени
MX2015003701A (es) Composiciones para tratamiento.
PH12016502559A1 (en) Isoindoline derivatives for use in the treatment of a viral infection
AU2013318309A8 (en) Methods for treating hepatitis C
MX348311B (es) Inhibidores nampt.
HK1208364A1 (en) Method for treating hepatitis c virus infection using quercetin- containing compositions
EA201890884A1 (ru) Способ и композиции для нежелательных и аномальных мышечных сокращений
IN2014DN00254A (es)
PH12016500903A1 (en) Novel methods for treating neurodegenerative diseases

Legal Events

Date Code Title Description
FG Grant or registration